ライフサイエンスコーパス: eosinophil count

1 and 1 year after (outcome) their most recent eosinophil count.

2 th vilanterol alone were not associated with eosinophil count.

3 limited to histologic EG based on the tissue eosinophil count.

4 pecified subgroup analysis by baseline blood eosinophil count.

5 to an increased body mass index or a reduced eosinophil count.

6 was assessed by induced sputum differential eosinophil count.

7 revalence, total immunoglobulin E (IgE), and eosinophil count.

8 lic inflammation, measured by induced sputum eosinophil count.

9 ations was independent of the baseline blood eosinophil count.

10 ting beta2 agonist, irrespective of baseline eosinophil count.

11 -course-persistent asthma had elevated blood eosinophil counts.

12 ced clinicopathologic remission with reduced eosinophil counts.

13 rated the ability to reduce blood and tissue eosinophil counts.

14 re not associated with changes in esophageal eosinophil counts.

15 zation significantly enhanced BAL and tissue eosinophil counts.

16 levels, blood eosinophil counts, and tissue eosinophil counts.

17 racterized by remodeling and variable airway eosinophil counts.

18 erapeutic agent, which correlated with lower eosinophil counts.

19 cantly predicted the presence of high sputum eosinophil counts.

20 SAC, which significantly correlated with BAL eosinophil counts.

21 eived placebo, independent of baseline blood eosinophil counts.

22 uid neutrophil and lymphocyte counts but not eosinophil counts.

23 1237 with high (>/=200 cells per muL) blood eosinophil counts.

24 mately 0, including correlations with sputum eosinophil counts.

25 between ETP and vWF with neutrophil but not eosinophil counts.

26 vere, uncontrolled asthma and elevated blood eosinophil counts.

27 counts, and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cells per

28 ively, active vs placebo) and gastric mucosa eosinophils counts (239 eosinophils/mm(2) [59-645] vs 25

29 e from baseline in the main peripheral blood eosinophil count 24 h after the fourth injection compare

30 ents were stratified (2:1) by baseline blood eosinophil counts 300 cells per muL or greater and less

31 f 75.1%, median values of 300/mm(3) of blood eosinophil count, 323 kU/L of serum total IgE, and 24 pp

32 0) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01).

33 nts or singly increased Feno levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%, P < .

34 ed nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/muL) than all other groups.

35 s' survival nor to serum IgE levels or blood eosinophil counts, a finding suggesting that this marker

36 se patients developed eosinophilia (absolute eosinophil count (AEC) > 500x 10/L) after day 100.

37 9 adult patients presenting with an absolute eosinophil count (AEC) of higher than 1.5 x 10(9)/L.

38 for the evaluation of eosinophilia (absolute eosinophil count [AEC] > 1500/muL) met the criteria for

39 recurred; with further treatment for 2 days, eosinophil counts again became normal.

40 Mucosal eosinophil count, age, sex, and current proton pump inhi

41 The ratio of eosinophil count (allergen to diluent) was linearly rela

42 The striking elevation in eosinophil counts among the TR group was accompanied by

43 a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizumab in

44 d persistent asthma irrespective of baseline eosinophil count and had a favourable safety profile, an

45 cus as well as novel loci for lung function, eosinophil count and IgE levels.

46 We investigated the relation between blood eosinophil count and prospective annual asthma outcomes

47 p) or by normalisation of the induced sputum eosinophil count and reduction of symptoms (sputum manag

48 most well established of these are the blood eosinophil count and serum periostin, both of which have

49 ve correlation between the percentage sputum eosinophil count and sputum PGE(2) concentration (r = -0

50 Peak eosinophil count and surface expression of eosinophil ac

51 acy measures were changes in peak esophageal eosinophil count and the physician's global assessment s

52 ifferentials, explaining 71% of variation in eosinophil counts and 64% of variation in neutrophil cou

53 count-response relation exists between blood eosinophil counts and asthma-related outcomes.

54 sociation between sputum or peripheral blood eosinophil counts and body mass index.

55 ficantly improved intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-re

56 sess the relationship between baseline blood eosinophil counts and efficacy of mepolizumab we did a s

57 osinophilic inflammation [primary endpoints: eosinophil counts and eosinophil cationic protein (ECP)]

58 Most patients had increased peripheral eosinophil counts and eosinophil percentages of white bl

59 Bronchoalveolar lavage (BAL) eosinophil counts and eotaxin levels were significantly

60 When combined with eosinophil counts and IgE levels, eotaxin levels contrib

61 eactions correlated with reductions in blood eosinophil counts and lung function and increases in nas

62 rleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of

63 r of controller medications, and total blood eosinophil counts and negatively with the Asthma Control

64 T-cell counts and positively correlated with eosinophil counts and not associated with CD4 T-cell cou

65 nd rs2416257 (A allele associated with lower eosinophil counts and protective against asthma) were co

66 ion of IL33 (A allele associated with higher eosinophil counts and risk for asthma) was correlated wi

67 Subjects performed spirometry, their eosinophil counts and serum total IgE were measured, and

68 ts with both increased Feno levels and blood eosinophil counts and subjects with normal Feno levels a

69 n serum immunoglobulin E (IgE) levels, blood eosinophil counts and three on lung function as measured

70 ic protein in nasal washes, along with blood eosinophil counts and total and allergen-specific IgE in

71 zed for hemoglobin, white blood cell counts, eosinophil counts and total serum IgE levels, questionna

72 and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in durat

73 lung disease alters BAL fluid neutrophil and eosinophil counts and whether the persistence of abnorma

74 ed on the basis of total IgE level and blood eosinophil count) and serum periostin level.

75 , 17 patients with asthma matched for sputum eosinophil count, and 10 normal subjects.

76 Low albumin level, low eosinophil count, and CDI treatment preenrollment were r

77 oking status, pack-years of smoking, weight, eosinophil count, and education).

78 Total serum IgE, eosinophil count, and FEV1% predicted levels were not as

79 ting for age, height, initial FEV1, smoking, eosinophil count, and IgE level, FEF25-75/FVC was signif

80 Other assessments included CD4 cell count, eosinophil count, and physician-assessed rash severity.

81 ance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical

82 ction of exhaled nitric oxide [Feno], sputum eosinophil count, and urinary bromotyrosine [BrTyr] leve

83 t pulmonary function tests, blood and sputum eosinophil counts, and 1.5-T DCE MR imaging within 7 day

84 production by IL-13-stimulated BECs, sputum eosinophil counts, and asthma severity.

85 ction correlated with PC20 for methacholine, eosinophil counts, and FEV1.

86 ne the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric oxide

87 d reduced OVA-induced increases in total and eosinophil counts, and IL-4, IL-5, IL-13, IL-1beta, IL-3

88 ling (in 82% of subjects), markedly elevated eosinophil counts, and increased filaria-specific immuno

89 was analyzed for relationships to diagnosis, eosinophil counts, and indices of subepithelial fibrosis

90 lar lavage fluid total cellularity, absolute eosinophil counts, and inflammation in the lung tissue.

91 C20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not

92 CD4(+) T lymphocyte counts, eosinophil counts, and plasma HIV-1 RNA concentrations w

93 questionnaire, spirometry, peripheral blood eosinophil counts, and testing for airway responsiveness

94 lammation, including serum IgE levels, blood eosinophil counts, and tissue eosinophil counts.

95 s had higher than normal Feno values, sputum eosinophil counts, and urinary BrTyr levels during the s

96 s (phase 2) during which Feno values, sputum eosinophil counts, and urinary BrTyr levels were measure

97 High pulmonary eosinophil counts are associated with asthma symptoms an

98 Using 2% baseline eosinophil count as a threshold, patients with COPD with

99 vely with nine ascending categories of blood eosinophil count as compared with a reference category o

100 screening periostin concentration, and blood eosinophil counts as covariates.

101 values of NSBH, and FeNO, as well as sputum eosinophil counts assessed at baseline of the SIC were d

102 ts, 243 patients (99.1%) had a normal or low eosinophil count at admission.

103 antibody against IL-5 lowered the mean blood eosinophil count at day 29 from 0.25x10(9)/L (95% CI 0.1

104 s posttreatment, preceding a peak peripheral eosinophil count at day 4.

105 lia before transplant, and in ten (71%), the eosinophil count at least doubled.

106 ere observed in patients regardless of blood eosinophil counts at enrollment.

107 All children had low lymphocyte and eosinophil counts at entry and high leukocyte and monocy

108 n the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per muL and were in

109 Blood eosinophil counts at screening were related to the exace

110 s was found among patients with higher blood eosinophil counts at screening.

111 rate for a greater than 75% decrease in peak eosinophil counts at week 12.

112 FeNO, airway responsiveness, blood eosinophil count (B-Eos) and IgE sensitization to food a

113 ion of exhaled nitric oxide (Feno) and blood eosinophil count (B-Eos) values, markers of local and sy

114 as a comparable decrease in peripheral blood eosinophil count beginning 5 h after challenge, which re

115 al, an effect not seen in most patients with eosinophil counts below these thresholds.

116 ing placebo was given according to the blood eosinophil count biomarker.

117 tment reduces STH prevalence, total IgE, and eosinophil count but has no effect on IR at the communit

118 inhibitor zileuton reduced postantigen BALF eosinophil count by 68% in the high LT producers, but ha

119 mptoms of eosinophilic esophagitis or tissue eosinophil counts compared with placebo.

120 ignificantly higher nucleated macrophage and eosinophil counts compared with sedentary control dogs.

121 ntly increased BAL fluid and biopsy specimen eosinophil counts compared with those found in control s

122 s, and FEV1 percent predicted, but not blood eosinophil counts, correctly predicted 69% of sputum eos

123 Blood eosinophil count could potentially be used to stratify p

124 Blood eosinophil counts could add predictive value to Global I

125 ials (conducted between 1998 and 2011), with eosinophil count data available for 10 861 patients with

126 ase from baseline of 61.9% in airway mucosal eosinophil counts (day 28; placebo: +19.6%; P = .28), as

127 200 mg) median reduction of 95.8% in airway eosinophil counts (day 84; placebo, 46.7%; P = .06), as

128 After treatment, peripheral eosinophil counts declined in ivermectin-treated groups

129 y end point was not met, the mean esophageal eosinophil count decreased by 60% with QAX576 versus an

130 The mean percentage sputum eosinophil count decreased significantly (p < 0.001) fro

131 creased in 82% of asthmatic patients, sputum eosinophil counts decreased in 60%, and urinary BrTyr le

132 Peak and mean esophageal intraepithelial eosinophil counts decreased significantly to 40.2 +/- 5.

133 moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatme

134 with recurrent exacerbations and high blood eosinophil counts despite use of inhaled corticosteroids

135 Tissue eosinophil counts did not correlate with CCL26 staining.

136 control children and were reflected in lower eosinophil counts during measles.

137 haled breath (FENO ), spirometry (FEV1 ) and eosinophil count (EOS) in 36 patients with allergic, ste

138 Increases in blood eosinophil counts (EOS) beyond 0.06 x 10(9)/liter preced

139 ere evaluated with respect to baseline blood eosinophil counts (eosinophils <300/muL [low] vs >/=300/

140 Intraepithelial peak eosinophil and blood eosinophil counts, esophageal-related symptoms, serum to

141 inophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and pred

142 The geometric mean sputum eosinophil count fell significantly after prednisolone (

143 We sought to determine whether blood eosinophil counts, Feno levels, and IgE levels accuratel

144 on with sputum eosinophil percentages, blood eosinophil counts, Feno levels, and total IgE levels did

145 sttreatment EMT was strongly correlated with eosinophil counts for combined (r = 0.804, P < .001) and

146 Baseline eosinophil counts for the NEB and OVB groups were 101 an

147 ed at weeks 1 and 4 with monitoring of blood eosinophil counts for up to 16 weeks.

148 eas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asth

149 c patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide leve

150 The combination of blood eosinophil count, fractional exhaled nitric oxide, Asthm

151 Patients with asthma and blood eosinophil counts greater than 400 cells per muL experie

152 , 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per muL.

153 -positive and -negative exacerbations (blood eosinophil count > and </= 2%, respectively).

154 Using either a PC20 </=16 mg/mL or a sputum eosinophil count >/=1% increased the sensitivity to 94%.

155 A FeNO level >/=25 ppb and a sputum eosinophil count >/=2% provided lower sensitivity rates

156 NSBH despite a positive SIC showed a sputum eosinophil count >/=2%, a FeNO level >/=25 ppb, or both

157 2.832, 95%-CI 1.508-5.321, P = 0.001), peak eosinophil count >10 eosinophils/HPF (OR 0.724, 95%-CI 0

158 phenotype were stratified according to blood eosinophil count (>/=150 per cubic millimeter at screeni

159 rate-to-severe asthma and an elevated sputum eosinophil count (>/=2%).

160 ) ratio versus placebo, analysed by baseline eosinophil counts (>/=0, >/=150, >/=300, or >/=450 cells

161 creased Feno levels (>/=20-25 ppb) and blood eosinophil counts (>/=0.3 x 10(9)/L) had a higher preval

162 erbations in patients stratified by baseline eosinophil counts (>/=150 cells per muL, >/=300 cells pe

163 itric oxide values in relationship to sputum eosinophil counts (>2%), as well as to determine whether

164 , 40 (3.8%) patients with less than 2% blood eosinophil counts had a pneumonia event versus 48 (2.4%)

165 reshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than did tho

166 We conclude that following the peripheral eosinophil count in children post-SCT is useful, and a r

167 n E (TIgE), serum-specific immunoglobulin E, eosinophil count in peripheral blood, and skin-prick tes

168 tiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum

169 with eosinophilic asthma and its effects on eosinophil counts in airway mucosal/submucosal biopsy sp

170 lter symptoms of eosinophilic esophagitis or eosinophil counts in biopsy samples compared with placeb

171 y mucosa/submucosa and sputum and suppressed eosinophil counts in bone marrow and peripheral blood.

172 ificantly reduced intraepithelial esophageal eosinophil counts in children and adolescents with eosin

173 inary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolerate and

174 vents eosinophilic degranulation and reduces eosinophil counts in primary biliary cirrhosis.

175 investigate increased Feno levels and blood eosinophil counts in relation to lung function, bronchia

176 ) and is correlated with high IgE levels and eosinophil counts in subjects bearing the risk genotype.

177 The mean peak eosinophil counts in the proximal esophagus were 34 eos/

178 For HIV-infected patients, the eosinophil count increased and the other blood cell comp

179 ipheral blood eosinophilia is present or the eosinophil count increases by at least two-fold.

180 Blood eosinophil count is a promising biomarker of response to

181 The peripheral blood eosinophil count is a promising biomarker to direct cort

182 We investigated whether blood eosinophil count is a useful biomarker of the long-term

183 treatment for COPD have shown that the blood eosinophil count is associated with the risk of COPD exa

184 ng with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment select

185 l due to clinical relevance]), rectal biopsy eosinophil count less than or equal to 32 cells per high

186 e that patients with COPD and baseline blood eosinophil counts less than 2% have a poorer response to

187 0% (0.79 vs 0.89; p=0.2827) in patients with eosinophil counts lower than 2%.

188 and allergic mediators, lower mast cells and eosinophil counts, lower protein expressions of Th2 cyto

189 The primary outcome was an eosinophil count <1.5 x 109/L at one month and improveme

190 >/=3%, and <5% and >/=5%) and absolute blood eosinophil count (<150 cells/mul, 150 to <300 cells/mul,

191 eumonia events, stratified by baseline blood eosinophil count (<2% vs >/=2% of blood leucocytes) and

192 itric oxide levels (<24 ppb), and (4) sputum eosinophil counts (<2.5%).

193 mly allocated them (1:1; stratified by blood eosinophil count [<300 cells per muL vs >/=300 cells per

194 al serum IgE level (median, 733 kU/L), blood eosinophil count (median, 400 cells/mm(3)), and allergen

195 n biopsy had significantly higher peripheral eosinophil counts (median, 330 vs 180/microL; P = .02) a

196 Blood eosinophil count mediated 29% of the life-course-persist

197 % and it was therefore postulated that blood eosinophil count might also have an effect on the risk o

198 Blood eosinophil counts might predict response to inhaled cort

199 s ratio, 32.6; P = 6.9 x 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 x 10(-6)), a

200 was histologic remission, defined by a peak eosinophil count of </=1 eosinophil in all 400x fields i

201 analyses, with 2083 patients (66%) having an eosinophil count of 2% or higher at study entry.

202 A total of 25.1% of cases had a peak mucosal eosinophil count of 20-59, 29.2% had a peak mucosal eosi

203 one acute exacerbation of COPD, and a sputum eosinophil count of 3.0% or more within the previous yea

204 Eosinophil count of 300 cells/muL or more and aeroallerg

205 hil count of 20-59, 29.2% had a peak mucosal eosinophil count of 60-100, and 45.7% had a peak mucosal

206 unction; an esophageal biopsy with a maximum eosinophil count of at least 15 eosinophils per high-pow

207 0.39-0.58) in patients with a baseline blood eosinophil count of at least 150 cells per muL to 70%; 0

208 In METREO, all patients had a blood eosinophil count of at least 150 per cubic millimeter at

209 stent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter or

210 aintain a stable clinical status and a blood eosinophil count of less than 1000 per microliter.

211 A blood eosinophil count of less than 600 per microliter for 8 o

212 ount of 60-100, and 45.7% had a peak mucosal eosinophil count of more than 100.

213 nthic therapy, but patients with an absolute eosinophil count of more than 3000/microL or more than 1

214 ol alone, were 24% in patients with baseline eosinophil counts of >/=2-<4%, 32% for those with counts

215 with counts of 4-<6%, and 42% for those with eosinophil counts of >/=6%.

216 received benralizumab every 4 weeks who had eosinophil counts of 0 or more cells per muL, AER was 0.

217 patient per year; p<0.0001) in patients with eosinophil counts of 2% or higher, and by 10% (0.79 vs 0

218 Patients with circulating eosinophil counts of 2% or more of blood leucocytes resp

219 than 2% and 6818 patients had baseline blood eosinophil counts of 2% or more.

220 th both aeroallergen sensitization and blood eosinophil counts of 300/muL or greater.

221 ds of asthma control for patients with blood eosinophil counts of 400 cells per muL or less versus gr

222 had eosinophilia, with median peak absolute eosinophil counts of 726/mL (interquartile range, 594-99

223 AER among patients with baseline blood eosinophil counts of at least 0 cells per muL was 1.16 (

224 ients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per muL and less

225 om score at week 48, for patients with blood eosinophil counts of at least 300 cells per muL.

226 (FEV1 in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per muL as

227 4043 patients had baseline blood eosinophil counts of less than 2% and 6818 patients had

228 exhaled nitric oxide (Feno) levels and blood eosinophil counts offer additive information in relation

229 The median eosinophil count on day 1 was 0.0 (interquartile range,

230 icant attenuation of allergen-induced sputum eosinophil count on Day 4 following GSK2190915: mean tre

231 Peripheral eosinophil counts on days 1 and 3 of admission and at th

232 No differences were documented in blood eosinophil counts or serum markers after eHF intake.

233 BHR than having normal Feno levels and blood eosinophil counts or singly increased Feno levels or blo

234 ients with increased serum IgE levels, blood eosinophil counts, or both were also negative.

235 the ICS-continuation group in patients with eosinophil counts (out of total white blood cell count)

236 Serum CCL17 correlated with eosinophil count (P < 0.0001, r = 0.73), but not with pr

237 levels significantly correlated with sputum eosinophil counts (P < .0001), suggesting that CCL26 par

238 caused similar decreases in peripheral blood eosinophil counts (P < 0.05 for each agent compared with

239 25) showed significantly higher circulating eosinophil counts (P <.

240 k UDCA treatment significantly reduced blood eosinophil counts (P <.0001) and serum MBP (P <.0001) an

241 d subjects with normal Feno levels and blood eosinophil counts (P = .02) after adjusting for confound

242 .001) and the highest quartile of peripheral eosinophil counts (P = .03) but not wheezing symptoms, b

243 scores correlated with increased airway wall eosinophil counts (P = 0.003), blood eosinophil percenta

244 Increased peripheral blood eosinophil counts (patients with EG: 1.09 +/- 0.88 x 10(

245 027) positively correlated with peak gastric eosinophil counts (Pearson r(2) = .8102, P < .0001).

246 ates increased progressively with increasing eosinophil count percentage category.

247 ter stratification into tertiles by baseline eosinophil count, postbronchodilator forced expiratory v

248 Elevated sputum eosinophil counts predict asthma exacerbations and respo

249 (P < .005) and was inversely correlated with eosinophil count (R = -0.67; P = .001).

250 42, p < 0.001) and with the peripheral blood eosinophil count (r = 0.34, p < 0.001) in the group of 6

251 sion was negatively correlated with absolute eosinophil counts (r = -0.46, P < .001), and soluble pla

252 ation found was between IgE levels and blood eosinophil counts (r = 0.33, P < .001); furthermore, all

253 a levels correlated positively with absolute eosinophil counts (r = 0.69, P < .001), suggesting modul

254 se or normal esophagus and was correlated to eosinophil counts (r = 0.691), eosinophil peroxidase (r

255 inical development program showed that blood eosinophil counts, rather than sputum or tissue eosinoph

256 weak but significant association with sputum eosinophil counts (receiver operating characteristic are

257 The geometric mean sputum eosinophil count reduced from 2.1% to 0.7% (P=0.03) afte

258 d reduced bronchoalveolar lavage (BAL) fluid eosinophil counts, reduced airway resistance in response

259 ected at normalisation of the induced sputum eosinophil count reduces asthma exacerbations and admiss

260 Having increased Feno levels and blood eosinophil counts related to a higher prevalence of mode

261 Eosinophil counts remained suppressed for up to 12 weeks

262 lasting more than three months in which the eosinophil count returned to normal.

263 After food reintroduction, esophageal eosinophil counts returned to pretreatment values (P < .

264 ho = 0.48), C-reactive-protein (rho = 0.43), eosinophil counts (rho = -0.45), and serum albumin (rho

265 EC) in the first 24 hours posttreatment, the eosinophil count rose significantly in both groups, peak

266 None developed recurrent symptoms, and eosinophil counts, serum B12, and tryptase levels remain

267 Blood eosinophil counts showed a weak but significant associat

268 ry end points included changes in esophageal eosinophil counts, symptoms assessed by questionnaire sc

269 s were found between collagen deposition and eosinophil count, TGF-beta expression level, FEV1, or du

270 tly higher total IgE levels and higher blood eosinophil counts than those with the lower-risk genotyp

271 neutrophilia, and despite the wide range in eosinophil counts, the T(H)2 mediators that are thought

272 o of the 4 patients responded with a fall in eosinophil counts to within the normal range within 48 h

273 Reduced peak and mean eosinophil counts, to <20 per hpf, were observed in 18 o

274 association study of plasma eotaxin levels, eosinophil counts, total IgE levels, asthma diagnosis, a

275 Variables, such as blood eosinophil counts, total IgE levels, fraction of exhaled

276 lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histologic ch

277 The mean blood eosinophil count was 200/muL (SD, 144/muL).

278 The peak gastric antrum eosinophil count was 283 +/- 164 eosinophils/x400 high-p

279 The sputum eosinophil count was 63% (95% CI 24-100) lower over 12 m

280 The geometric mean sputum eosinophil count was similar in asthma (13.4%) and eosin

281 Four weeks after the third infusion, peak eosinophil counts were <5 per hpf in 5 of 57 children (8

282 were classified as responders if their peak eosinophil counts were <or=6 eos/hpf, partial responders

283 ine peak and mean esophageal intraepithelial eosinophil counts were (mean +/- SE) 122.5 +/- 8.78 and

284 DSQ scores were 29.3 and 29.0, and mean peak eosinophil counts were 156 and 130 per hpf in the BOS an

285 DSQ scores were 15.0 and 21.5, and mean peak eosinophil counts were 39 and 113 per high-power field,

286 ine to the end of therapy in peak esophageal eosinophil counts were 59%, 67%, 64%, and 24% in the 1,

287 Mean pre-/post-treatment peak eosinophil counts were 66.7 and 4.8 eos/hpf, respectivel

288 Feno levels and sputum eosinophil counts were assessed at baseline and 24 hours

289 ionships with pulmonary function testing and eosinophil counts were assessed by using Pearson correla

290 Measurements of Feno levels and blood eosinophil counts were available in 406 subjects (208 wo

291 Increased IgE concentrations and eosinophil counts were found after sepsis and do not app

292 Eosinophil counts were greater in patients with sepsis (

293 Blood eosinophil counts were increased in bilirubin-treated an

294 plasma concentrations of IgE, and peripheral eosinophil counts were prospectively collected.

295 f gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with EG and

296 hilic inflammation, some have an increase in eosinophil counts, which might be orchestrated by TH2 ce

297 b in patients with asthma and elevated blood eosinophil counts who are inadequately controlled on inh

298 her mean baseline esophageal intraepithelial eosinophil count with a greater reduction in mean count

299 protocol presented a significant increase in eosinophil counts with increased extracellular DNA in br

300 whether patients with COPD with higher blood eosinophil counts would be more likely to have exacerbat